Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Diabetes drugs worth the risks

  • Comment
EUROPEAN drug regulators have said the benefits of diabetes drugs rosiglitazone and pioglitazone outweigh any potential cardiovascular risks, despite recent research.

EUROPEAN drug regulators have said the benefits of diabetes drugs rosiglitazone and pioglitazone outweigh any potential cardiovascular risks, despite recent research.

However, the European Medicines Agency also said prescribing information should include a warning that, in patients with ischaemic heart disease, rosiglitazone should only be used after careful evaluation of individual risk.

Additionally, rosiglitazone and insulin should only be used together in exceptional cases and under close supervision.
Tracy Kelly, a care adviser at Diabetes UK, said nurses should screen and monitor patients taking the drugs. ‘But the risks are so small in the grand scheme of things,’ she added.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.